Phosphodiesterase 4 inhibitors for chronic obstructive pulmonary disease
Cochrane database of systematic reviews, November 2013
Chong, Jimmy, Leung, Bonnie, Poole, Phillippa
Chronic obstructive pulmonary disease (COPD) is associated with cough, sputum production or dyspnoea and a reduction in lung function, quality of life and life expectancy. Apart from smoking cessation, there are no other treatments that slow lung function decline. Roflumilast and cilomilast are oral phosphodiesterase 4 (PDE4) inhibitors proposed to reduce the airway inflammation and bronchoconstriction seen in COPD.
The data shown below were collected from the profiles of 12 tweeters who shared this research output. Click here to find out more about how the information was compiled.
|Members of the public||9||75%|
|Science communicators (journalists, bloggers, editors)||1||8%|
|Practitioners (doctors, other healthcare professionals)||1||8%|
The data shown below were compiled from readership statistics for 167 Mendeley readers of this research output. Click here to see the associated Mendeley record.
|Readers by professional status||Count||As %|
|Student > Master||38||23%|
|Student > Postgraduate||14||8%|
|Student > Bachelor||14||8%|
|Readers by discipline||Count||As %|
|Medicine and Dentistry||58||35%|
|Nursing and Health Professions||11||7%|